Evatanepag(CP-533536)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	223488-57-1
规格:	≥98%

包装与价格：

包装	价格(元)
2mg	电议
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议

产品介绍

Evatanepag (formerly known as CP-533536; CP-533536 free acid) is a novel, potent and selective agonist of EP2 receptor prostaglandin E2 (PGE2). It induces local bone formation with EC50 of 0.3 nM. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.

理化性质和储存条件

Molecular Weight (MW)	468.57
Formula	C25H28N2O5S
CAS No.	223488-57-1
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: ≥ 32 mg/mL
	Water: N/A
	Ethanol: N/A
SMILES Code	O=C(O)COC1=CC=CC(CN(CC2=CC=C(C(C)(C)C)C=C2)S(=O)(C3=CC=CN=C3)=O)=C1
Synonym	Evatanepag; CP-533536; CP 533536; CP533536; Chemical Name: 2-(3-((N-(4-(tert-butyl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid

实验参考方法

In Vitro	In vitro activity: Evatanepag (formerly known as CP-533536) is a potent and selective agonist of EP2 receptor prostaglandin E2 (PGE2). It induces local bone formation with EC50 of 0.3 nM. C Kinase Assay: Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.
In Vivo	P-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.
Animal model	Rats
Formulation & Dosage	Administered locally as a single dose
References	Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8.